公开(公告)号：US11712448B2

公开(公告)日：2023-08-01

申请号：US15106196

申请日：2014-12-19

Applicant: ALGIPHARMA AS

Inventor： Arne Dessen ,  Philip Rye

IPC: A61K31/734 ,  A61P7/02 ,  A61K31/702 ,  A61M1/36 ,  A61L33/08 ,  A61K31/715

CPC classification number: A61K31/734 ,  A61K31/702 ,  A61K31/715 ,  A61L33/08 ,  A61M1/3673 ,  A61P7/02 ,  A61L33/08 ,  C08L5/04

Abstract: The disclosure relates to an alginate oligomer of 2 to 75 monomer residues, wherein said monomer residues do not carry a sulphate group, for use as a blood anticoagulant in clinical and non-clinical applications, including in vivo, ex vivo and in vitro contexts. The invention further provides for the use of such an alginate oligomer in preparing a product or device having a reduced capacity to promote blood coagulation, wherein said alginate oligomer is provided at or on a surface of said product or device. Such products and devices form a further aspect of the invention.

公开(公告)号：US20180235879A1

公开(公告)日：2018-08-23

申请号：US15507712

申请日：2015-08-28

Applicant: AlgiPharma AS

Inventor： Bildad NYAMBURA ,  Anand BAKLE ,  Arne DESSEN

IPC: A61K9/00 ,  A61K9/16 ,  A61P11/00 ,  A61K9/48

CPC classification number: A61K9/0075 ,  A61K9/008 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/1682 ,  A61K9/4808 ,  A61P11/00

Abstract: Spray dried particles are for inhalation. The particles consist of (i) at least about 70% w/w of an alginate oligomer, (ii) at least about 10% w/w in total of a phospholipid and an anti-adherent compound. and (iii) no greater than about 10% w/w of further excipients. The phospholipid is solid at room temperature, and is present at no less than 0.5% w/w. The anti-adherent compound is present at no less than 0.5% w/w. The particles, capsules and dry powder inhalers including the particles can be for therapeutic use, such as in the treatment or reduction of likelihood of a respiratory infection or a respiratory disorder.

公开(公告)号：US20210386666A1

公开(公告)日：2021-12-16

申请号：US17445577

申请日：2021-08-20

Applicant: AlgiPharma AS

Inventor： Bildad NYAMBURA ,  Anand BAKLE ,  Arne DESSEN

IPC: A61K9/00 ,  A61K9/16 ,  A61P11/00 ,  A61K9/48

Abstract: A method of preparing spray dried particles for inhalation comprising providing: (i) an aqueous liquid composition including the alginate oligomer and an aqueous liquid composition including an anti-adherent compound, or (ii) an aqueous liquid composition including the alginate oligomer and an anti-adherent compound; providing an organic liquid composition including a phospholipid; combining a volume of the organic liquid composition with a volume of the aqueous liquid composition, wherein the total volume of the organic liquid composition is smaller than the total volume of the aqueous liquid composition with which it is combined, and wherein the total volume of aqueous liquid composition and said total volume of organic liquid composition are sufficient to provide a combination; homogenizing the combination to form an organic-in-aqueous liquid emulsion for spray drying; and spray drying the organic-in-aqueous liquid emulsion to form the spray dried particles for inhalation.

公开(公告)号：US20210030891A1

公开(公告)日：2021-02-04

申请号：US16982240

申请日：2019-03-19

Applicant: AlgiPharma AS

Inventor： Aristides Tagalakis ,  Stephen Hart ,  Are Kristiansen ,  Arne Dessen ,  Philip D. Rye

IPC: A61K47/69 ,  A61K47/61 ,  C12N15/113

Abstract: A method for translocating a cationic micro/nanoparticle across a mucus layer, the method including (a) contacting the mucus layer with at least one alginate oligomer, the alginate oligomer having at least 70% mannuronate residues, together with the cationic micro/nanoparticle; or (b)(i) contacting the cationic micro/nanoparticle with an alginate oligomer having at least 70% mannuronate residues thereby forming a micro/nanoparticle carrying the alginate oligomer, and (b)(ii) contacting the mucus layer with the micro/nanoparticle prepared in step (b)(i). There is also provided a method for translocating a molecule of interest across a mucus layer including contacting the mucus layer with a micro/nanoparticle which is formed of self-assembling micro/nanoparticle forming components, wherein at least one is a cationic micro/nanoparticle forming agent and at least one is an alginate oligomer which has at least 70% mannuronate residues, and further comprises the molecule of interest, optionally wherein the molecule of interest is covalently bound to one or more of the self-assembling micro/nanoparticle forming components.

公开(公告)号：US20160331777A1

公开(公告)日：2016-11-17

申请号：US15106196

申请日：2014-12-19

Applicant: ALGIPHARMA AS

Inventor： Arne DESSEN ,  Philip RYE

IPC: A61K31/734 ,  A61M1/36 ,  A61L33/08

CPC classification number: A61K31/734 ,  A61K31/715 ,  A61L33/08 ,  A61M1/3673 ,  C08L5/04

Abstract: The disclosure relates to an alginate oligomer of 2 to 75 monomer residues, wherein said monomer residues do not carry a sulphate group, for use as a blood anticoagulant in clinical and non-clinical applications, including in vivo, ex vivo and in vitro contexts. The invention further provides for the use of such an alginate oligomer in preparing a product or device having a reduced capacity to promote blood coagulation, wherein said alginate oligomer is provided at or on a surface of said product or device. Such products and devices form a further aspect of the invention.

Abstract translation: 本公开涉及2至75个单体残基的藻酸盐低聚物，其中所述单体残基不携带硫酸盐基团，用于临床和非临床应用中的血液抗凝血剂，包括体内，离体和体外环境。 本发明还提供了这样的藻酸盐低聚物在制备具有降低的促进血液凝固能力的产品或装置中的用途，其中所述藻酸盐低聚物提供在所述产品或装置的表面上或表面上。 这样的产品和装置形成本发明的另一方面。

公开(公告)号：US20230139922A1

公开(公告)日：2023-05-04

申请号：US16343629

申请日：2017-10-20

Applicant: AlgiPharma AS

Inventor： Elaine Ferguson ,  David William Thomas ,  Arne Dessen ,  Philip D. Rye

IPC: A61K47/61 ,  A61K38/12 ,  A61P31/04

Abstract: A bacitracin-alginate oligomer conjugate including a bacitracin-class antibiotic connected covalently to at least one alginate oligomer via a direct covalent bond or a covalent molecular linker, or a pharmaceutically acceptable salt, solvate, hydrate, diastereoisomer, tautomer, enantiomer or active metabolite thereof. Also provided are methods for the preparation of the conjugate, pharmaceutical compositions comprising the conjugate and the use thereof in a method for the treatment or prevention of a bacterial infection in a subject with, suspected to have, or at risk of, a bacterial infection.

公开(公告)号：US09877983B2

公开(公告)日：2018-01-30

申请号：US14221691

申请日：2014-03-21

Applicant: ALGIPHARMA AS

Inventor： Edvar Onsoyen ,  Rolf Myrvold

IPC: A61K31/734 ,  A61K8/73 ,  A61Q19/00 ,  A61K8/66 ,  A61K31/65 ,  A01N43/16 ,  A61K38/48 ,  A61K45/06 ,  A61K31/7036 ,  A01N63/02 ,  A01N65/03 ,  A61Q11/00 ,  A61Q17/00

CPC classification number: A61K31/734 ,  A01N43/16 ,  A01N63/02 ,  A01N65/03 ,  A61K8/66 ,  A61K8/733 ,  A61K31/65 ,  A61K31/7036 ,  A61K38/4886 ,  A61K45/06 ,  A61Q11/00 ,  A61Q17/005 ,  A61Q19/007

Abstract: The invention provides a method for combating biofilm, said method comprising contacting a biofilm with an alginate oligomer. The biofilm may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use in the treatment or prevention of a biofilm infection in a subject. In another aspect the method can be used to combat biofilms, on abiotic surfaces, e.g. for disinfection and cleaning purposes.

公开(公告)号：US20140205643A1

公开(公告)日：2014-07-24

申请号：US14221691

申请日：2014-03-21

Applicant: ALGIPHARMA AS

Inventor： EDVAR ONSOYEN ,  ROLF MYRVOLD

IPC: A61K31/734 ,  A61K8/73 ,  A61Q19/00 ,  A61K8/66 ,  A61K31/65 ,  A01N43/16 ,  A61K38/48 ,  A61K45/06 ,  A61K31/7036

CPC classification number: A61K31/734 ,  A01N43/16 ,  A01N63/02 ,  A01N65/03 ,  A61K8/66 ,  A61K8/733 ,  A61K31/65 ,  A61K31/7036 ,  A61K38/4886 ,  A61K45/06 ,  A61Q11/00 ,  A61Q17/005 ,  A61Q19/007

Abstract: The invention provides a method for combating biofilm, said method comprising contacting a biofilm with an alginate oligomer. The biofilm may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use in the treatment or prevention of a biofilm infection in a subject. In another aspect the method can be used to combat biofilms, on abiotic surfaces, e.g. for disinfection and cleaning purposes.

Abstract translation: 本发明提供了一种防治生物膜的方法，所述方法包括使生物膜与藻酸盐低聚物接触。 生物膜可以在生物或无生命的表面上，并且提供医疗和非医疗用途和方法。 一方面，本发明提供了用于治疗或预防受试者中生物膜感染的藻酸盐低聚物。 在另一方面，该方法可用于对抗生物膜，在非生物表面上，例如， 用于消毒和清洁目的。

公开(公告)号：US20220305050A1

公开(公告)日：2022-09-29

申请号：US17596741

申请日：2020-06-17

Applicant: AlgiPharma AS

Inventor： Rhodri Williams ,  Phillip Adrian Evans ,  Arne Dessen ,  Philip Rye

IPC: A61K31/734 ,  A61P7/02

Abstract: An alginate oligomer for use in the anticoagulation therapy of a human or non-human vertebrate subject at risk of blood clots which have an abnormally dense microstructure. In certain embodiments, the incidence of blood clots which have an abnormally dense microstructure in the subject is reduced and/or the occurrence of blood clots which have an abnormally dense microstructure in the subject is inhibited and/or the abnormal microstructure of the subject's clots is normalized. Corresponding methods of anticoagulation therapy and products of use therein are further provided.

公开(公告)号：US11413306B2

公开(公告)日：2022-08-16

申请号：US15766272

申请日：2016-10-06

Applicant: AlgiPharma AS

Inventor： Arne Dessen ,  Philip Rye

IPC: A61K31/734 ,  A61P31/10 ,  A61K9/00 ,  A61K45/06 ,  A61K31/165 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4375 ,  A61K31/47 ,  A61K31/7036 ,  A61K31/4178 ,  A61K31/365 ,  A61K31/4245 ,  A61K31/352 ,  A61K31/192 ,  A61K36/03 ,  A61K31/522 ,  A61K31/4422 ,  A61P31/04

Abstract: The invention provides a method for the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject, said method comprising administering an effective amount of an alginate oligomer to a subject in need thereof. Also provided is an alginate oligomer for use in the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject and a product containing an alginate oligomer and further pharmaceutical for the treatment of intestinal microbial overgrowth and/or a CFTR modulator as a combined preparation for separate, simultaneous or sequential use in the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject.